Pliant Therapeutics PLRX
Pliant Therapeutics FY 2020: revenue $41.8M; diluted EPS −$1.95
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-21-013589
- Document
- 10-K
- Exhibit 4.3
- Warrants or notes
Key figures from this report
These are the numbers Pliant Therapeutics reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$41.8MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$41.5MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$1.95No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$50.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$37.3MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025
- Seres Therapeutics MCRB public float $72M, Jun 30, 2025
- Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
- Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
- Volitionrx VNRX public float $73M, Jun 30, 2025